Cefoxitin Injection

Compare Cefoxitin Injection  to:
Compare
Compare

Generic Name for Cefoxitin Injection

Cefoxitin sodium 1g, 2g; for IV inj; sodium content 2.3mEq/g.

Legal Classification:

Rx

Pharmacological Class for Cefoxitin Injection

Cephalosporin.

Manufacturer of Cefoxitin Injection

Various generic manufacturers

Indications for Cefoxitin Injection

Susceptible bacterial septicemia, lower respiratory or urinary tract, skin and skin structure, bone and joint, gynecologic, intraabdominal infections. Surgical prophylaxis.

Adult dose for Cefoxitin Injection

Usually 1–2g every 6–8 hrs. Uncomplicated: 1g every 6–8 hrs. Moderately severe to severe: 1g every 4 hrs or 2g every 6–8 hrs. Max 2g every 4 hrs or 3g every 6 hrs. Prophylaxis: see literature.

Children's dosing for Cefoxitin Injection

<3months: not recommended. ≥3months: 80-160mg/kg per day in 4–6 equal divided doses; max 12g/day. Prophylaxis: see literature.

Precautions for Cefoxitin Injection

Penicillin or other allergy. Renal impairment (CrCl <50mL/min), reduce dose: see literature. GI disease (esp. colitis). Pregnancy (Cat.B). Nursing mothers.

Interactions for Cefoxitin Injection

Aminoglycosides may potentiate nephrotoxicity. Potentiated by probenecid. May cause false (+) Clinitest. May interfere with creatinine tests.

Adverse Reactions for Cefoxitin Injection

Local reactions, rash, pruritus, drug fever, GI upset, anaphylaxis, blood dyscrasias, elevated liver enzymes.

How is Cefoxitin Injection supplied?

Contact supplier.

Related Disease:

Infections, bacterial~systemic antiinfectives

Related Resources

Cayston inhaled antibiotic approved for cystic fibrosis

February 23, 2010

The FDA has approved Cayston (aztreonam for inhalation solution, from Gilead Sciences) as a treatment to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa.

Phase 3 study of fidaxomicin for clostridium difficile infection (CDI)

February 05, 2010

Optimer Pharmaceuticals announced positive top-line results from the second of two Phase 3 trials evaluating the safety and efficacy of fidaxomicin (OPT-80) in patients with Clostridium difficile Infection (CDI).

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Phase 2 study of Arikace for treatment of pseudomonas lung infections

October 19, 2009

Transave reported additional positive clinical trial results on its lead investigational drug, Arikace (liposomal amikacin for inhalation), an antibiotic to treat chronic lung infections.

Vibativ approved for complicated skin and skin structure infections

September 18, 2009

The FDA has approved Vibativ (telavancin, from Theravance and Astellas), a bactericidal, once-daily injectable lipoglycopeptide antibiotic.